[A24-09] Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85
Last updated 15.02.2024
Project no.:
A24-09
Commission:
Commission awarded on 09.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Combination therapy with bevacizumab for the treatment of adults with metastatic colorectal cancer who have received 2 prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and/or anti-epidermal growth factor receptor agents
After addendum now: indication of major added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A24-09_en
| Project no. | Title | Status |
|---|---|---|
| A23-85 | Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.